从 2014 年警告信到 2026 年 Form 483，PharmaBuddy 解读 Olympia 的 8 条观察项

从警告信到 2026 再中招：Olympia 这份 483，把"验证"二字彻底写成了空话

Olympia（OPS International Inc dba Olympia Pharmaceuticals）在佛罗里达奥兰多做 503B 外包配制——2013 年自愿召回全部无菌产品，2014 年挨 FDA 警告信，2018、2025 年连吃两份 483。2026 年 9 月 3 日，第十一 天检查结束，最新的8 条 483又来了。翻完这 8 条，一个词最刺眼：验证。

互动 一家外包设施，灭菌后部件能放多久居然"没有证据"——你觉得这在无菌生产里算小事吗？

一、背景：一家"资格最老"的 503B，和它十二年绕不开的监管史

这家公司是做什么的。OPS International Inc，商业名 Olympia Pharmaceuticals，注册地址在佛罗里达州奥兰多 6700 Conroy Rd Ste 155，FDA 登记类别是"外包设施"（Outsourcing Facility，即 503B）。它是行业里资格最老、渠道最广的 503B 之一：同时在 49 个州持证，产品线横跨减重、激素、男性健康与 IV 营养四大热点——Myer's Cocktail（迈耶鸡尾酒营养液）、NAD+ 100mg/ml、T-105（罂粟碱/酚妥拉明/前列地尔，男性功能复方）、甘油 48%/利多卡因、Niagen、Olympia Mineral Blend、L-牛磺酸、生物素、Sermorelin 等。这类"高频输液 + 复方注射"业务对无菌保障的要求极高，也因此一直是 FDA 佛罗里达办公室的重点盯防对象。

签字的是谁。483 的接收人是药房总监（Director of Pharmacy）Michael A. Bogard。签署人两名检查员：Mindy M. Chou与Michelle Lin，均为 FDA 调查员，来自佛罗里达 Maitland 办公室（555 Winderley Place, Suite 200）。两人签发日期为 2026 年 9 月 3 日。这份 483 的写作风格非常"现场派"：直接引用观察到的技师编号、批号、精确到分钟的作业时间戳（如"08:01 开始装配、08:06 完成"），还有烟雾研究视频的具体时间码（如 3:26–4:22 的湍流画面）——都是当场盯着看的记录。

十二年监管史。Olympia 的档案几乎是一部 503B 教科书式的"循环"：2013 年，因无菌操作问题自愿召回全部无菌产品；2014 年，收到 FDA 警告信（FLA-14-04）；2018 年 4 月 13 日，再吃 10 条观察项的 483；2025 年 8 月 8 日，又一份 8 条的 483；到 2026 年 8 月 20 日至 9 月 3 日的本次检查——连续 11 个工作日（8/20、21、24、25、26、27、28、31，9/1、2、3），是本批 5 家企业里检查时间最长的之一。换句话说，FDA 用了两周时间逐条验证：上一个循环的教训，学到了没有。

这次检查怎么跑的。检查员现场观看的作业包括：8 月 20 日氨基酸混合液（Amino Blend，批号 H11A03-26）的灯检、8 月 21 日生物素 0.5mg/ml（H17A05-26）灌装线的无菌装配、8 月 26 日氯化钙（H24A01-26）自动灌装机装配、9 月 1 日灭菌柜装载状态核查。8 条观察项里几乎每条都带着"we observed"——这份 483 的地基不是文件审查，是现场目击。

二、逐条拆解：8 条，英文原文 + 中文还原

（以下每条中文表述均以 483 原文为据，并按上下文补全原文未言明之处以便阅读；(b)(4) 为 FDA 官方脱敏处，照原文保留；依上下文推测的内容以「（推断）」标出，非原文内容。）

观察项 1｜环境监测系统缺陷：最脏的装配时刻，恰好不监测

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. Specifically, (A) The firm's environmental monitoring procedure does not require viable environmental monitoring during the initial aseptic setup of the (b)(4) filling line within the (b)(4), or during the initial aseptic setup of the (b)(4) automated filling machine positioned under (b)(4) HEPA-filtered unidirectional airflow enclosure. Per SOP-009, Environmental Monitoring of the Controlled Production Areas, environmental monitoring is not required to commence until aseptic connections setup activities have occurred. (1) On August 26, 2026, we observed operator performing set-up of the (b)(4) for the (b)(4) automated filling machine (Equipment ID #(b)(4)) for the filling of Calcium Chloride (Lot #H24A01-26). No environmental monitoring plates were present within the ISO 5 critical area under the (b)(4) unidirectional airflow unit during this setup activity. (2) According to the batch record for Myer's Cocktail (Lot# G27A05-26, Exp. 26 Nov 2026), equipment set-up of the (b)(4) auto filler, located inside the ISO (b)(4) in Suite (b)(4) began at 08:01. The first passive air sample was not opened until 08:21 on 30 July 2026. (B) The firm's personnel monitoring program does not include microbiological monitoring of gown locations for Sterile Techs who perform set-up of the (b)(4) filling line or set-up of the (b)(4) automated filling machine. Gown monitoring at a defined schedule, supported by scientific justification, is not included in the program. (1) On August 21, 2026, we observed Sterile Tech performing line setup for the filling of Biotin 0.5 mg/ml (Lot# H17A05-26) with his head, body, and sleeves inside the ISO 5 (b)(4) chamber without any concurrent personnel monitoring. (2) On August 26, 2026, we observed Sterile Tech performing set up for the filling of Calcium Chloride (Lot #H24A01-26) with his sleeves inside the ISO 5 (b)(4) HEPA-filtered unidirectional airflow enclosure (LAFW: (b)(4)). The automated (b)(4) filling machine (b)(4) operates under (b)(4) HEPA-filtered unidirectional airflow enclosure with no physical barrier between the filling operation and the operator. (C) Gloved fingertip monitoring of the Sterile Tech is performed only following completion of the aseptic filling production shift.

无菌加工区的环境监测系统存在缺陷，三处：

装配期不监测。按 SOP-009《受控生产区的环境监测》，环境监测要到“无菌连接装配开始之后”才启动——也就是说，最脏的装配阶段完全不在监测范围内。8 月 26 日，操作员为氯化钙（批号 H24A01-26）装配自动灌装机（设备编号 (b)(4)）时，单向流装置下方 ISO 5 关键区里一只监测培养皿都没有。Myer's Cocktail（批号 G27A05-26）的批记录同样显示：设备装配 7 月 30 日 08:01 开始，第一只被动空气采样皿到 08:21 才打开——晚了整整 20 分钟。

人员监测不含工装。程序里没有对无菌技师洁净服部位的微生物监测，既没有规定日程，也没有科学依据。8 月 21 日，一名技师为生物素 0.5mg/ml（批号 H17A05-26）做灌装线装配，头、身体和袖子都伸进了 ISO 5 (b)(4) 腔体，全程没有任何同步人员监测；8 月 26 日，另一名技师为氯化钙装配时袖子伸进 ISO 5 (b)(4) HEPA 单向流罩——而那台自动灌装机就在单向流罩下运行，灌装操作与操作员之间没有任何物理屏障。

指尖只在下班后采。无菌技师的手套指尖监测，只在无菌灌装班次结束之后才做，覆盖不到生产过程中的污染暴露。

FDA 的真实关切：装配是洁净区里人员干预最密集、最容易带入污染的时刻，监测却从装配之后才开始；人的手臂直接悬在敞口灌装位上方，工装和指尖统统不在监测范围。整套 EM 只拍"干净的时候"。法规：21 CFR 211.113(b)；USP <1116>、ISO 14644 理念。

观察项 2｜污染防控规程未建立/未遵守：从无菌保持、腔体消毒到烟雾研究全线失守

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed. Specifically, (A) Your firm has not adequately demonstrated that (b)(4)-sterilized machine (b)(4) parts and accessories used in aseptic filling maintain their sterile state during the established (b)(4) post-sterilization hold time in a controlled, non-classified area. The supporting microbiological evaluation consisted of swabbing part surfaces and incubating samples in (b)(4) medium (b)(4) for (b)(4). (1) Your firm has not provided adequate scientific justification that these incubation conditions are suitable for recovering and detecting microorganisms that may be encountered if the sterile barrier is compromised during storage within the non-classified area. (2) The provided records associated with the sampling, in-house incubation, and results of the swab samples lacked the following critical information: i. Actual incubation temperature; ii. Date and time samples were placed in the incubator; iii. Date and time samples were removed from the incubator; iv. Identity of the person who read the results. (3) According to your Senior Quality Manager and Senior Director of Compliance, following the in-house incubation of the swab samples, the samples were sent to your contract laboratory for sterility testing; however, the associated records, including the third-party sterility test results, could not be located. (B) On August 21, 2026, during aseptic setup of the (b)(4) filling line for Biotin 0.5 mg/ml (Lot# H17A05-26), Chamber(s) (Material Chamber) (b)(4) were (b)(4), exposing the (b)(4) surfaces to the ISO 7 environment. Subsequently the (b)(4) were (b)(4) without disinfecting the exposed (b)(4) surfaces, thereby reintroducing ISO 7 environmentally exposed surfaces into the ISO 5 critical area. (C) Your firm has not adequately established a visual inspector qualification program to demonstrate that personnel can consistently and reliably detect microbial growth during the visual inspection of media-filled units. (1) Your challenge qualification(s) contain (b)(4) prepared with (b)(4) in (b)(4) vials and (b)(4). Your firm has no documented scientific justification for the use of (b)(4) as a surrogate for actual microbial contamination/turbidity. (2) There is no documented justification for the number, type, and distribution of positive units to demonstrate reliable contamination detection in media fills filled in (b)(4) vials. (3) (b)(4) vials are used to simulate your (b)(4) mL and (b)(4) mL vialing process during aseptic process simulation (APS). You have not evaluated whether turbidity can be adequately detected in these vials. (D) Your 2026 smoke studies, conducted as per PRO-029-01, Smoke Study Protocol, and PRO-029-03, (b)(4) Airflow Visualization Protocol, did not adequately qualify unidirectional airflow or demonstrate first air and acceptable airflow patterns during critical operations. For example: (1) Airflow patterns could not be adequately assessed in multiple (b)(4) chambers and the (b)(4) HEPA-filtered unidirectional airflow unit due to obstructions, glare, inadequate smoke introduction technique, and/or camera angle limitations. (2) In (b)(4) Chamber (b)(4), turbulent eddies were observed near a (b)(4) (video time point: (b)(4) 3:26-4:22), and smoke was observed exiting and briefly re-entering the chamber near the top when the (b)(4) during setup (video time point: (b)(4) 4:40-4:55). (3) The studies simulated routine activities, including line setup, loading of vials, stoppers and caps, and cleaning; however, the only corrective intervention evaluated was removal of a vial from the filling line using (b)(4). Your firm did not provide an adequate assessment demonstrating that the interventions selected represent reasonably foreseeable corrective interventions and worst-case aseptic manipulations during production. The affected equipment includes: i. (b)(4) in Suite (b)(4) housing the (b)(4) filling line used for sterile drug products such as Myer's Cocktail, NAD+ (β-Nicotinamide Adenine Dinucleotide) 100 mg/ml Injection, and MICC Injection. ii. (b)(4) HEPA-filtered unidirectional airflow enclosures (LAFW (b)(4), LAFW-(b)(4), LAFW-(b)(4)) in Suite (b)(4), housing (b)(4) automated filler(s) (b)(4), used for sterile drug products such as Niagen 100 mg/ml, Olympia Mineral Blend, and L-Taurine. Your smoke study report, PRO-029-02, Smoke Study Protocol: FINAL REPORT (approved 02 June 2026), and RPT-PRO-029-03, (b)(4) Airflow Visualization Report (approved 07 August 2026), both concluded that the smoke studies successfully demonstrated unidirectional airflow during dynamic operations.

为防止“声称无菌”的药品受微生物污染而设计的程序，既没建立也没被遵守，四块：

A. 灭菌后能放多久，没有证据。企业未能证明：经 (b)(4) 灭菌的机器部件与配件，在既定的 (b)(4) 灭菌后保持时限内、存放在受控但非分级区域时仍能维持无菌。支撑这一结论的“微生物评估”只是擦一擦表面、放进 (b)(4) 培养基培养 (b)(4)：既没有科学依据说明这套培养条件能回收和检出“无菌屏障在非分级区存放期间一旦被破坏可能遇到的微生物”，记录里还缺了实际培养温度、进箱与出箱的日期时间、以及读结果的人是谁。更糟的是，据企业高级质量经理与高级合规总监说，内部培养后样品送去了合同实验室做无菌检查——相关记录连同第三方结果，找不到了。

B. 暴露过 ISO 7 的表面，不消毒就回 ISO 5。8 月 21 日生物素 0.5mg/ml（批号 H17A05-26）灌装线无菌装配期间，物料腔被打开，(b)(4) 表面暴露在 ISO 7 环境中；随后这些部件被直接装回——暴露面未做任何消毒，等于把沾着 ISO 7 环境的表面重新带进 ISO 5 关键区。

C. 灯检员能不能看见“长菌”，没人证明过。企业没有建立充分的资质程序，证明人员能在培养基灌装单位的灯检中持续、可靠地检出微生物生长：挑战样品是用 (b)(4) 配制的 (b)(4)，却没有任何书面依据说明它为什么能替代真实的微生物污染/浑浊；阳性瓶的数量、类型与分布同样没有依据；无菌工艺模拟（APS）用 (b)(4) 瓶去模拟 (b)(4) ml 与 (b)(4) ml 的灌装过程，企业从未评估过浑浊在这种瓶子里到底能不能被看清。

D. 烟雾研究拍到了问题，报告写的是“成功”。2026 年按 PRO-029-01 与 PRO-029-03 做的烟雾研究，未能充分确认单向流，也未能证明关键操作期间存在 first air 与可接受的气流流型：多个 (b)(4) 腔体与 (b)(4) HEPA 单向流装置因遮挡、眩光、烟雾注入手法不当、机位受限而无法评估；某腔体视频 3:26–4:22 处可见 (b)(4) 附近的湍流涡旋，装配时视频 4:40–4:55 处可见烟雾从腔体顶部流出后又短暂倒灌回来。研究只模拟了装配、装瓶/塞/盖、清洁等常规动作，唯一评估的纠正性干预只是“从灌装线取走一支瓶”，没有证明所选干预代表了可合理预见的纠正干预与最差无菌动作。受影响设备包括 (b)(4) 洁净间的 (b)(4) 灌装线（Myer's Cocktail、NAD+ 100mg/ml、MICC 注射液），以及 (b)(4) 洁净间的三台 HEPA 单向流罩及其自动灌装机（Niagen 100mg/ml、Olympia Mineral Blend、L-牛磺酸）。而企业自己的报告 PRO-029-02（2026/6/2 批准）与 RPT-PRO-029-03（2026/8/7 批准），结论都是“成功证明了动态操作期间的单向流”。

FDA 的真实关切：这一条的信息密度极高——无菌保持的验证用"擦一擦"充数、记录连温度和读数人都没有、第三方结果直接丢失；物料腔曝在 ISO 7 里消毒都不做就回 ISO 5；烟雾研究自己拍出了湍流、自己却写"成功"。最扎眼的是最后这个反差：视频里明明有涡流，报告里写的是合格。法规：21 CFR 211.113(b)；USP <797>/<1207>。

互动 "灭菌后放多久还算无菌"都说不清，这台设备你还敢用吗？

观察项 3｜书面规程不执行：5 分钟完成多腔室装配、灯检漏步骤、灭菌装载图对不上

Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance. Specifically, (B) Batch record review of Myer's Cocktail (Lot# G27A05-26, Exp. 26 Nov 2026) revealed that equipment set-up of the (b)(4) filling line, located inside the ISO 5 (b)(4) in Suite (b)(4) began on 30 July 2026 at 08:01 and was completed by Sterile Tech (b)(4) at 08:06 on 30 July 2026 - a total elapsed time of five minutes. However, set-up encompassed installation of (b)(4) chambers, where each require multiple set up steps. For example, the (b)(4) chamber alone required the installation of multiple components, including the (b)(4), and other associated parts. (C) Visual inspectors did not perform via (b)(4) as required by Section 9.3 of SOP-007, Visual Inspection of Sterile Drug Products, and inspection steps performed in practice differed from those written in the procedure. (1) On August 20, 2026, Sterile Tech was observed conducting visual inspection of Amino Blend (Lot# H11A03-26) and failed to perform vial (b)(4). When subsequently asked to describe the inspection procedure, Sterile Tech was again unable to identify vial (b)(4) as a required step. (2) On August 21, 2026, Sterile Tech was observed performing visual inspection of Biotin 0.5 mg/ml (Lot# H17A05-26) and similarly failed to perform vial (b)(4). (D) On September 1, 2026, the (b)(4) (Equipment ID: (b)(4)) was observed loaded with (b)(4) on August 28, 2026. Notably, the (b)(4) was loaded with (b)(4) on (b)(4); however, your currently approved procedure, SOA-040-01, Sterilization Load Configurations, effective 05 June 2026, specifies a (b)(4) load pattern diagram of only (b)(4).

书面的生产与工艺控制程序在实际执行中没被遵守，也没有在操作发生时同步记录，三处：

装配只用了五分钟。Myer's Cocktail（批号 G27A05-26）批记录显示：(b)(4) 洁净间 ISO 5 内 (b)(4) 灌装线的设备装配，7 月 30 日 08:01 开始、08:06 完成，总耗时五分钟。而这次装配要装 (b)(4) 个腔体，每个腔体都有多道步骤——光 (b)(4) 腔体就要装 (b)(4) 等多个部件。五分钟装不完，说明记录不是同期写实。

灯检漏步骤。灯检员未按 SOP-007《无菌药品灯检》第 9.3 节执行 via (b)(4)，实际动作与书面规程不一致：8 月 20 日，一名技师灯检氨基酸混合液（批号 H11A03-26）时漏做西林瓶 (b)(4)；被要求复述流程时，他仍然说不出这一步是必需的。8 月 21 日，另一名技师灯检生物素 0.5mg/ml（批号 H17A05-26），同样漏做。

灭菌装载对不上自家图纸。9 月 1 日检查发现，(b)(4)（设备编号 (b)(4)）在 8 月 28 日的装载方式，与现行批准规程 SOA-040-01《灭菌装载配置》（2026/6/5 生效）规定的 (b)(4) 装载图不一致。

FDA 的真实关切：规程写着一套、现场做着另一套，批记录的 5 分钟装配时间戳本身就是"没有如实同期记录"的自供状。法规：21 CFR 211.100(b)。

观察项 4｜灯检员资质：挑战样品的微粒"连大小都没测过"

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess. Specifically, the (b)(4) visual inspection qualification (b)(4) used to qualify personnel performing 100% visual inspection of injectable drug products are not adequately characterized or designed to challenge inspectors' ability to detect particulates at or near the threshold of visual detectability. For example: (A) Your firm has not established the size or size range of the particulate defects contained in the qualification units intended to challenge visual inspectors to detect the smallest contaminants possible for an inspector with 20/20 vision. Although (b)(4) defect vials containing particulates were submitted for size characterization, the analysis was performed using the particle-size distribution method described in USP <429>, as documented in the Certificates of Analysis. The resulting data do not establish the size of the individual particulate defect contained in each qualification unit. (B) No written procedures or records exist documenting the preparation and contents of each particulate defect unit, including particulate type, size or size range, and method of preparation. This information is known only to the individual who prepared the qualification (b)(4).

企业没有建立充分的生产与工艺控制书面程序，来保证药品具备其声称的质量属性。问题出在灯检员的资格确认装置上——它既没有充分表征，设计上也不足以挑战检查员检出“处于或接近视觉可检阈值”的微粒：

A. 连“考题有多大”都没测过。企业没有确定资格确认装置里那颗微粒缺陷的粒径或粒径范围，而这些装置本该用来挑战灯检员检出 20/20 视力所能看到的最小污染物。含微粒的缺陷瓶虽然送做过表征，但用的是 USP <429> 的粒度分布方法（CoA 里有记录）——分布给的是一群粒子的统计结果，无法确定每个确认装置里那一颗缺陷微粒的实际大小。

B. 考题怎么出的，只有出题人知道。没有任何书面程序或记录写明每个微粒缺陷装置的配制过程与内容物：微粒类型、粒径或粒径范围、制备方法统统没有——这些信息只掌握在制备该 (b)(4) 的那个人手里。

FDA 的真实关切：灯检是微粒入体的最后一道闸，而这套"考试题"既没有标准答案（粒径未知）、出题过程还只掌握在一个人手里——考试本身无法证明任何人的能力。法规：USP <790>（目视检查）、<429>（粒径分布）。

观察项 5｜稳定性方法没有质量平衡：Sermorelin 的效期建立不可信

The written stability program for drug products does not include reliable, meaningful and specific test methods. Specifically, your firm assigns a (b)(4) beyond-use date (BUD) to Sermorelin Acetate 0.9 mg/ml Injection based on your contract laboratory stability study. However, your firm failed to provide adequate demonstration that the analytical procedure can detect relevant degradation-related changes. Your method validation report for Sermorelin Acetate, approved on August 22, 2025, does not include a mass balance assessment to demonstrate that the analytical method can adequately account for the drug substance and its degradation products, supporting the method's stability-indicating capability and reliability.

药品的书面稳定性程序里，没有可靠、有意义、有专属性的检验方法。企业给醋酸舍莫瑞林（Sermorelin Acetate）0.9mg/ml 注射液定了 (b)(4) 的使用期（BUD），依据是合同实验室的稳定性研究，却拿不出证据证明所用分析方法能检出相关的降解变化——2025 年 8 月 22 日批准的方法验证报告里没有质量平衡（mass balance）评估，也就是无法证明该方法能把原料药和它的降解产物完整地“对上账”。多肽极易降解，缺了这一项，方法的稳定性指示能力与可靠性都没有支撑，BUD 也就悬空了。

FDA 的真实关切：多肽类药物极易降解；没有质量平衡的稳定性方法等于只测"还剩多少"而不问"变成了什么"，BUD 是没有地基的。法规：21 CFR 211.166；ICH Q1A/Q2。

观察项 6｜无菌部件状态标识：胶塞碗没有灭菌标签，也没人核对

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products. Specifically, (A) Your firm utilizes (b)(4) QA-access-controlled cabinets for the storage of sterilized machine parts and accessories. (b)(4). During inspection of these cabinets (b)(4) components, including a stopper bowl that directly contacts product stoppers, were observed without sterilization-status labels. The components lacked information identifying the applicable (b)(4) and sterilization date needed for personnel to determine whether the established sterile hold time had been exceeded. (B) Sterilization-status labels are generated by operators; however, the firm did not demonstrate a system for reconciling generated labels to the individual equipment parts associated with each sterilization cycle.

为防止污染或混淆而设的隔离与限定区域，在无菌加工相关操作上失守：

A. 无菌件没有状态标签。企业用 (b)(4) 个 QA 门禁受控柜存放灭菌后的机器部件与配件。检查这些柜子时，(b)(4) 个部件没有任何灭菌状态标签——其中包括一个直接接触产品胶塞的胶塞碗。它们缺少标明适用 (b)(4) 与灭菌日期的信息，人员根本无法判断既定的无菌保持时限有没有被超过。

B. 标签和部件对不上账。灭菌状态标签由操作员自行生成，但企业拿不出任何体系，能把生成的标签与每个灭菌周期所对应的单个设备部件核对一致。

FDA 的真实关切：这条与观察项 2(A) 直接联动——"保持时限"本身没有验证，柜子里的部件又没有标签、没有台账，双重失守后"超时无菌件"可以无声地进入下一批生产。法规：21 CFR 211.42；状态标识管理原则。

观察项 7｜组分检测缺失：甲醇、二甘醇这些"剧毒项"没测

Component testing is deficient in that each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality. Specifically, (A) SOP-035, Procurement, Receipt, and Inspection of Incoming Components and Materials, does not include a sampling plan specifying the number of containers to be sampled per shipment. According to the Senior Supply Chain Manager, (b)(4) sent from your (b)(4) warehouse to your facility for sampling. Additionally, no documentation exists for the sampling performed. (B) Your firm failed to perform a specific identity test that includes a methanol limit test on each container of each lot of ethyl alcohol used as a pharmaceutical ingredient. On May 12, 2025, your firm received (b)(4) bottles of (b)(4) Ethyl Alcohol (b)(4) Proof (Batch #(b)(4)); (b)(4) sampled, and methanol limit testing was not performed. This lot was used in the production of T-105 Injection (Papaverine Hydrochloride 30 mg/ml; Phentolamine Mesylate 1 mg/ml; Alprostadil 0.01 mg/ml), Lot #G08A10-26, BUD 04 JUL 2027. (C) Your firm failed to test each container of each lot of glycerin, used as a pharmaceutical ingredient, for diethylene glycol (DEG) or ethylene glycol (EG) contamination. Your firm did not provide a scientifically sound justification, supported by statistical analysis, for reduced sampling. On September 25, 2025, your firm received (b)(4) bottles of Glycerin, NF (b)(4) (Lot #(b)(4)); however, (b)(4) sampled and tested for this shipment. Additionally, Lot #(b)(4) was tested only for Identification A and was not tested for DEG and EG prior to release for use. This lot was used in the production of Glycerin 48%/Lidocaine 0.33% Injection (Lot #E20A10-26; BUD 10 JAN 2027).

组分检测存在缺陷——每个组分都没有按全部适当的书面纯度、规格与质量标准逐项检测，三条：

A. 连取样计划都没有。SOP-035《来料组分的采购、接收与检查》里没有取样计划，不规定每批货该取多少个容器。据供应链高级经理说，(b)(4) 从 (b)(4) 仓库送来设施取样；而实际取过样这件事，没有任何记录。

B. 乙醇没做甲醇限度。对作为药用成分使用的乙醇，企业没有对每批货的每个容器做含甲醇限度的专属鉴别。2025 年 5 月 12 日收到 (b)(4) 瓶 (b)(4) 乙醇（(b)(4) Proof，批号 (b)(4)），只取样了 (b)(4)，甲醇限度试验没有做——这个批号用在了 T-105 注射液（罂粟碱 HCl 30mg/ml、甲磺酸酚妥拉明 1mg/ml、前列地尔 0.01mg/ml）的生产中，批号 G08A10-26，BUD 2027 年 7 月 4 日。

C. 甘油没做 DEG/EG。对药用甘油，企业没有对每批货的每个容器检测二甘醇（DEG）或乙二醇（EG）污染，也没有给出经统计支持的减少取样理由。2025 年 9 月 25 日收到 (b)(4) 瓶 NF 甘油（批号 (b)(4)），该批货只取样检测了 (b)(4)；批号 (b)(4) 更是只做了鉴别 A，放行使用前没测 DEG/EG——它用在了甘油 48%/利多卡因 0.33% 注射液（批号 E20A10-26，BUD 2027 年 1 月 10 日）的生产中。DEG/EG 污染甘油在历史上造成过多国数百人死亡（1937 年美国“磺胺酏剂事件”直接催生了 1938 年《联邦食品药品化妆品法》），甲醇是同类剧毒杂质——这两项从来是零容忍。

FDA 的真实关切：DEG/EG 污染甘油在历史上造成过多国数百人死亡（包括 1937 年美国的"磺胺酏剂事件"，这正是 1938 年《联邦食品药品化妆品法》的立法起点），甲醇是同类剧毒杂质。FDA 对这两个项目的态度从来是零容忍——没有任何妥协余地。法规：21 CFR 211.84(d)；USP <467> 残留溶剂理念。

互动 二甘醇进注射剂是什么后果？这条，没有任何妥协余地。

观察项 8｜加料无双人复核：两小时后补一个时间戳

Each component is not added to the batch by one person and verified by a second person. Specifically, a review of the batch record for Myer's Cocktail (Lot (b)(4), Exp (b)(4)) revealed that ingredients were added between (b)(4) on July 29, 2026, with no documented contemporaneous verification recorded after each individual addition. Instead, a single verification timestamp of (b)(4) was documented for this manufacturing step, more than two hours after the last ingredient was added.

每一组分本应一人加入、第二人复核，实际不是这样。Myer's Cocktail（批号 (b)(4)）批记录显示：2026 年 7 月 29 日，各组分是在 (b)(4) 之间陆续加入的，每一次单独加料之后都没有同期复核记录。整个生产步骤只写了一个复核时间戳 (b)(4)——比最后一个组分加完晚了两个多小时。双人复核是防“加错料、加错量”的最后一道人工闸门；事后补一个时间戳，等于这道闸门从来没真正合上过。

FDA 的真实关切：双人复核是防"加错料、加错量"的最后一道人工闸门；事后补一个时间戳，等于这道闸门从未真正合上过。法规：21 CFR 211.101。

三、主线收敛

8 条读到尾，主线就一句："凡是需要'验证'的地方，Olympia 都没做。"EM 起点错位（1）、灭菌保持与烟雾研究无证据（2）、规程与现场两张皮（3）、灯检考试无答案（4）、稳定性方法缺质量平衡（5）、无菌件无标识（6）、剧毒杂质不检测（7）、双人复核走形式（8）。最刺眼的对比是：烟雾研究视频里明明拍到了湍流，批准下来的报告却写着"成功证明单向流"——验证体系已经从"做不做"的问题，滑到了"做假"的边缘。

四、严重度一览

五、把这份 483 放回执法链条上看

Olympia 在这条链条上已经走了十二年：2013 年召回、2014 年警告信（FLA-14-04）、2018 年 10 条 483、2025 年 8 条 483、2026 年 8 条 483。对 FDA 而言，"警告信之后再犯"和"483 重复项"是两种不同量级的问题——前者证明的不是一个缺陷，而是一套体系改不动。这份 483 里分量最重的两条线索，一是观察项 2 里"烟雾研究拍到了湍流、报告却写成功"的验证失真，二是观察项 7 里"DEG/EG 未测即放行"的毒性杂质风险——前者动摇信任，后者直接踩在患者安全红线上。放在本批检查序列里看，它与 Imprimis、RC Outsourcing 同属 503B 序列，共同短板是无菌验证与执行双缺；Olympia 的特殊性在于监管史最长，"屡查屡犯"的记录会让每一个缺陷都被放到放大镜下看。

当然，Form 483 本身不是最终判定。企业仍有回复与申诉的程序空间，FDA 也尚未公布分类结论——以上是风险方向，不是判决书。

互动 从 2014 年警告信到 2026 年的 8 条，你认为是什么让"整改"在这家企业失效了十二年？

声明：本文基于美国 FDA 公开的执法文书（Form 483 / Warning Letter / Import Alert 等）撰写，仅供医药行业质量管理与合规学习交流之用，不构成对任何企业的法律或商业评价。原始文书以 FDA 官网公布版本为准；文书内容不构成 FDA 的最终判定。